ESR1 and breast cancer: In patients with stage II-III breast cancer, achievement of pCR to neoadjuvant chemotherapy correlates with improved long-term outcomes, however the predictive value of the standard clinical biomarkers such as ER, PR and HER2 is limited, motivating this study to identify factors mediating response.